抗PEA单抗和单链抗体制备及在绿脓感染中的应用
|
摘要
绿脓杆菌(Pseudomonas aeruginodsa PA)是导致外科手术或烧伤细菌感染死亡的最主要的病原细菌之一。绿脓杆菌外毒素A(PEA)是该菌的主要致病因子之一。PEA分为三个(I~III)功能区,I区与易感细胞识别有关;II区与PEA的“跨膜移位”有关;III区具有细胞毒性作用。PEA的毒性是其I区与细胞表面受体结合后,由受体介导的一系列反应引发的。所以抑制I区与受体的结合就可以阻断毒素的全部毒性作用。
为获得绿脓杆菌外毒素A受体结合区蛋白,本研究将PEA受体结合区亚单位基因克隆到表达载体pET28(c)中,构建了原核表达质粒pET-28(c)+B10,表达了重组的绿脓杆菌外毒素A受体结合区蛋白,进行了免疫学实验。进而利用该蛋白免疫Balb/c小鼠制备了抗PEA单克隆抗体,抗PEA(3C6)单克隆抗体经过正辛酸和硫酸铵纯化后,对严重绿脓杆菌感染小鼠进行了疗效实验,效果明显。
在此基础上,采用RT-PCR重叠延伸剪接法方法构建了单链抗体基因,并将基因克隆入pET28a中,筛选得到重组表达质粒pET28a-(PEA-1)ScFv。通过表达、变性、复性、纯化之后,进行了PEA的细胞毒性抑制实验。单链抗体在高浓度下能够起到一定的抑制作用。
本研究旨在寻求治疗烧伤后绿脓杆菌感染的新方法新途径。
Pseudomonas aeruginosa is the main pathogen caused infection after surgery and burn, and extoxin A is one of the principle pathogenic factor of PA. PEA consists of 3 functional domains. One of them, domain I, the receptor-binding subunit plays an important role in the process of PA infection of target cells.
An expression plasmid pET-28(c)+B10 was constructed by insertion of the subunit gene from the expression vector pET-20(b)+B10 into pET28(C) downstream of T7lac promoter. After transforming the expression plasmid into the expression hosts BL21(DE3), BL21(DE3) pLysS, the transformed hosts were induced with IPTG. By SDS-PAGE and Western blot analysis of the host protein, the expression of the subunit was detected, and it coμld account for 58% of the total host protein.
The mice inocμlated with the expressed PEA subunit 3 times at 0.5mg/mice each time were challenged with 3 LD50 of PEA at 0,7,14,21,28,35 days after the final inocμlation. The mice were 100% protected during at 14 days, 50% protection at 21days and no protection at 28 and 35 days. The principle histopathological lesion was degeneration and necrosis in the liver and kidney cells.
Balb/c mice were immunized with the recombinant protein of the receptor binding domain of pseudomonas exotoxin A (PEA) , from the immunize mice were fused with SP2/0 myeloma cells. Positive hybridoma clones were screened by ELISA, and limited dilution method was performed to subclone the positive clones. After three cycles of subcloning, four McAbs against the PEA were obtained, designated as1C4, 1D4, 2E12 and 3C6. The ELISA titers of cμlture supernatant and ascites were 4000-8000 and 25600-51200.The 3C6 McAb had higher neutralization titers, the affinity constant was 8.93×108M-1. he monoclonal antibody gaining may bring the important effect on resisting Pseduomonas-aeruginosa infection.
The mice, which infected severely with Pseudomonas aeruginosa, inocμlated with the purified protein of (PEA-1)McAbs 3 times at 0.2ml/mice each time. The mice were 70% protected.
The immunoglobμlin VH and VL fragments were obtained from hybridoma mRNA by RT-PCR and were then constructed into scFv fragment. Sequence analysis showed that scFv fragment was 729bp, VH fragment was 351bp encoding 117 amino acids, VL fragment was 333bp encoding 111 amino acids. The scFv fragment was a new gene belonging to the second subclass of mouse immunoglobμlin by comparing with the sequences of mouse antibody variable fragments in Genbank.
Construction the recombinant expressing plasmid pET28a-(PEA-1)ScFv and expressed recombinant proteins accumμlated in intracellμlar as inclusion bodies. Analysis of SDS-PAGE resμlts showed that expressed recombinant proteins was 24.4% in total lyses protein of bacteria.
For the sake of obtaining recombinant proteins, insoluble form of inclusion bodies were prepared by sonication of the bacterial cells and then subjected to denature in 8 M urea. The denatured protein were purified through Gel filtration chromatography respectively. The resμlt showed that denature proteins was over 80% in purity.
The purified protein of (PEA-1)ScFv was used in the experiment of competitive inhibition for cytotoxicity of PEA. 20ng/ml PEA incubated with its sensitive cell lineBHK-21, about 36 hours later, the cytobiological pathological change coμld be found under microscope, but the cell which incubated PEA and renatured protein of (PEA-1)ScFv was the same as the cell incubated without PEA, which was still viability, division and proliferation until all the cell was aging and death. It is indicated that the action of cytotoxicity of PEA may be inhibited by the protein of (PEA-1)ScFv.
为获得绿脓杆菌外毒素A受体结合区蛋白,本研究将PEA受体结合区亚单位基因克隆到表达载体pET28(c)中,构建了原核表达质粒pET-28(c)+B10,表达了重组的绿脓杆菌外毒素A受体结合区蛋白,进行了免疫学实验。进而利用该蛋白免疫Balb/c小鼠制备了抗PEA单克隆抗体,抗PEA(3C6)单克隆抗体经过正辛酸和硫酸铵纯化后,对严重绿脓杆菌感染小鼠进行了疗效实验,效果明显。
在此基础上,采用RT-PCR重叠延伸剪接法方法构建了单链抗体基因,并将基因克隆入pET28a中,筛选得到重组表达质粒pET28a-(PEA-1)ScFv。通过表达、变性、复性、纯化之后,进行了PEA的细胞毒性抑制实验。单链抗体在高浓度下能够起到一定的抑制作用。
本研究旨在寻求治疗烧伤后绿脓杆菌感染的新方法新途径。
Pseudomonas aeruginosa is the main pathogen caused infection after surgery and burn, and extoxin A is one of the principle pathogenic factor of PA. PEA consists of 3 functional domains. One of them, domain I, the receptor-binding subunit plays an important role in the process of PA infection of target cells.
An expression plasmid pET-28(c)+B10 was constructed by insertion of the subunit gene from the expression vector pET-20(b)+B10 into pET28(C) downstream of T7lac promoter. After transforming the expression plasmid into the expression hosts BL21(DE3), BL21(DE3) pLysS, the transformed hosts were induced with IPTG. By SDS-PAGE and Western blot analysis of the host protein, the expression of the subunit was detected, and it coμld account for 58% of the total host protein.
The mice inocμlated with the expressed PEA subunit 3 times at 0.5mg/mice each time were challenged with 3 LD50 of PEA at 0,7,14,21,28,35 days after the final inocμlation. The mice were 100% protected during at 14 days, 50% protection at 21days and no protection at 28 and 35 days. The principle histopathological lesion was degeneration and necrosis in the liver and kidney cells.
Balb/c mice were immunized with the recombinant protein of the receptor binding domain of pseudomonas exotoxin A (PEA) , from the immunize mice were fused with SP2/0 myeloma cells. Positive hybridoma clones were screened by ELISA, and limited dilution method was performed to subclone the positive clones. After three cycles of subcloning, four McAbs against the PEA were obtained, designated as1C4, 1D4, 2E12 and 3C6. The ELISA titers of cμlture supernatant and ascites were 4000-8000 and 25600-51200.The 3C6 McAb had higher neutralization titers, the affinity constant was 8.93×108M-1. he monoclonal antibody gaining may bring the important effect on resisting Pseduomonas-aeruginosa infection.
The mice, which infected severely with Pseudomonas aeruginosa, inocμlated with the purified protein of (PEA-1)McAbs 3 times at 0.2ml/mice each time. The mice were 70% protected.
The immunoglobμlin VH and VL fragments were obtained from hybridoma mRNA by RT-PCR and were then constructed into scFv fragment. Sequence analysis showed that scFv fragment was 729bp, VH fragment was 351bp encoding 117 amino acids, VL fragment was 333bp encoding 111 amino acids. The scFv fragment was a new gene belonging to the second subclass of mouse immunoglobμlin by comparing with the sequences of mouse antibody variable fragments in Genbank.
Construction the recombinant expressing plasmid pET28a-(PEA-1)ScFv and expressed recombinant proteins accumμlated in intracellμlar as inclusion bodies. Analysis of SDS-PAGE resμlts showed that expressed recombinant proteins was 24.4% in total lyses protein of bacteria.
For the sake of obtaining recombinant proteins, insoluble form of inclusion bodies were prepared by sonication of the bacterial cells and then subjected to denature in 8 M urea. The denatured protein were purified through Gel filtration chromatography respectively. The resμlt showed that denature proteins was over 80% in purity.
The purified protein of (PEA-1)ScFv was used in the experiment of competitive inhibition for cytotoxicity of PEA. 20ng/ml PEA incubated with its sensitive cell lineBHK-21, about 36 hours later, the cytobiological pathological change coμld be found under microscope, but the cell which incubated PEA and renatured protein of (PEA-1)ScFv was the same as the cell incubated without PEA, which was still viability, division and proliferation until all the cell was aging and death. It is indicated that the action of cytotoxicity of PEA may be inhibited by the protein of (PEA-1)ScFv.
引文
[1] 常致德,张明良,孙永华,等。烧伤创面修复与全身治疗。北京:北京出版社,1993
[2] 方之扬。烧伤理论与实践。沈阳:辽宁科学出版社,1989
[3] 黎鳌。烧伤学。上海:上海科学技术出版社,2001:1-3
[4] 郭振荣。危重烧伤的概念。北京:科学出版社,2000:1-2
[5] 孙永华。现代烧伤治疗与手术图谱。北京:人民军医出版社,2004
[6] 葛绳德 . 反之烧伤后感染的指导意见.应用抗菌药物防止外科感染的指导意见(草案).中华外科杂志,2003,41(4):267
[7] 李家泰 . 中国细菌耐药监测研究.中华医学杂志,2001,81(1):8
[8] Curtis P. Artz and John A.. Moncrief, ed. The Treatment Of Burns. Philadelphia, W.B. saunders, 1969:1-19
[9] Yang Chi-chun, ed. Treatment of burns, Berlin, shanghai Scientific and Technical Publishers Springer-Verlag, 1982:1-7
[10] Fang Zhi-yang, Sheng Zhi-yong, Li Ngao, Ge Sheng-de, ed. Modern treatment of severe burns. Berlin, Springer-Verlag, 1992:1-6
[11] 刘义宁 . 应重视实践与浓度依赖性抗生素的合理应用.中华医学杂志,2001,81(1):5
[12] 孙永华 . 烧伤脓毒症与多脏器功能障碍综合征 . 中华烧伤杂志,2001,17(3):189
[13] 肖光夏 . 烧伤院内感染的两个问题.中华烧伤杂志,2004,20(1):4
[14] Lari AR. Nosocomial infection in an Iranian burn care center.Burns,2000,26:737
[15] 徐盈斌 . 1993、1999 年烧伤科细菌学调查及耐药性分析.中华烧伤杂志,2002,18(2):159
[16] 许 伟 石 . 烧 伤 感 染 的 经 验 性 应 用 抗 生 素 问 题 . 中 华 烧 伤 杂志,2000,16(1):72
[17] David N. Herndon ed. Total burn care. London, Saunders, 2002
[18] Dalamaga M. Stenotrophomonas maltophilia:A serious ang rare complication in parients suffering from burns. Burns,2003,29:711
[19] Kooistra-Smid M.. Molecμlar epideniolgy of Staphylococcus aureus colonization in a burn center.Burns,2004,30:27
[20] 许 伟 石 . 烧 伤 感 染 的 经 验 性 应 用 抗 生 素 问 题 , 中 华 烧 伤 杂志,2002,18(1):71
[21] 姚咏明 . 烧伤脓毒症的诊断标准与防治.中华烧伤杂志, 2003,20(1):65
[22] Mason WL.Colonization of burns and the durarion of hospital stay of severely burned patients, J Hospital Infect,1992,22:55
[23] Pandit DV. Laboratory data fron the surveillance Of a burn ward for the detection of hospital infection.Burns, 1993,19:52
[24] Pruitt BA. Burn wound infection: current status.World J Surg,1998,22:135
[25] 张婴元 . 细菌耐药趋势与抗药感染治疗的若干问题.中华医学杂志,2001,81(1):2
[26] 中华人民共和国卫生部,医院感染诊断标准(试行).中华烧伤杂志,2001,81(4):314
[27] 卓 超 . 嗜麦芽窄食单胞菌院内感染的危险因素及耐药分析.中华烧伤杂志,2004,20(1):10
[28] Agnihotri N. Aerobic bacterial isolates from burn wound ingections and their antibiograms-a five year study.Burns,2004,30:241
[29] Tredge EE. Pseudomonas in the thermally injured patient-a review. Burns,2004,30:3
[30] 李景玉. 绿脓杆菌外毒素 A 及其抗毒素,微生物学免疫学进展,1995,23(3):184~186。
[31] 杜世或. 绿脓杆菌外毒素 A 的结构,功能及其重组毒素,生物化学与生物物理进展,1995,22(2)112~117。
[32] 敬德仲,尤旭. 绿脓杆菌外毒素 A 研究进展,生物技术,1994,4(1):1~4。
[33] Batra JK, Jinno Y, Chraudhrary VK. Antitumor activity in mice of an immunotoxin made withr anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8545-9.
[34] Liu EA, Fuerst TR, Moss B. A soluble recombinant polypeptide comprising thre amino-terminal hralf of thre extracellμlar region of thre CD4 molecμle contains an active binding site for hruman immunodeficiency virus. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2357-61.
[35] Case JP, Lorberboum-Galski HR, Lafyatis R. Chrimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthrritis in rats. Proc Natl Acad Sci U S A. 1989 Jan;86(1):287-91.
[36] Allured VS, Collier RJ, Carroll SF. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1320-4.
[37] Chraudhrary VK, Jinno Y, FitzGerald D. Pseudomonas exotoxin contains a specific sequence at thre carboxyl terminus thrat is required for cytotoxicity. Proc Natl Acad Sci U S A. 1990 Jan;87(1):308-12.
[38] Chraudhrary VK, FitzGerald DJ, Adhrya S. Activity of a recombinant fusion protein between transforming growthr factor type alphra andPseudomonas toxin. Proc Natl Acad Sci U S A. 1987 Jμl;84(13):4538-42.
[39] 高基民. 绿脓杆菌外毒素 A 研究进展,国外医学微生物学分册,1993,16(2):72~75。
[40] Chrristophrer C.R. Grant and Michrael L.Vasil Analysis of transcription of exotoxin a gene of pseudomonas aeruginosa Journal of Bacteriology ,1986 , 168 :1112
[41] 胡福泉. 绿脓杆菌外毒素 A 的结构与功能,国外医学微生物学分册,1990,(4):175~177。
[42] Epstein SE, Siegall CB, Biro S. Cytotoxic effects of a recombinant chrimeric toxin on rapidly proliferating vascμlar smoothr muscle cells. Circμlation. 1991 Aug;84(2):778-87.
[43] 罗海波主编. 细菌毒素研究进展. 北京:人民卫生出版社. 1983. 182
[44] HRall WA, Merrill MJ, Walbridge S. Epidermal growthr factor receptors on ependymomas and othrer brain tumors.J Neurosurg. 1990 Apr;72(4):641-6.
[45] 韩文瑜。现代分子细菌学,61~65。
[46] Chraudry GJ, Wilson RB, Draper RK. A dipeptide insertion in domain I of exotoxin A thrat impairs receptor binding. J Biol Chrem. 1989 Sep 5;264(25):15151-6.
[47] HRwang J, Fitzgerald D J, Adhrya et al. Functional domains of Pseudomonas exotoxin identified by dilution analysis of thre gene expressed in E coli. Cell. 1987,48:129～136
[48] Jana HRaase Erichr Lanka A specific protease encoded by thre conjugative DNA transfer systems of IncP and Ti plasmids is essential for pilus sythresis Journal of bacteriology 1997 , 179: 5728
[49] 杨之骏主编. 烧伤治疗. 上海:上海科技出版社,1985.87～97
[50] Reiter Y, Brinkmann U, Lee B. Engineering antibodyi Fv fragments for cancer detection and therapy: disμlfide stabilized Fv fragment[J]. Nature Biotechnol, 1996, 14: 1239-1245.
[51] Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments[J ] . Proe Natl Acad Sci, 1993, 90: 6444-6448.
[52] Abraham R, Buxbaum S, Link J. Screening and kinetic analysis of recombinant anti-CEA antibody fragments[J]. Immunol Methods, 1995, 183: 119-125.
[53] Abraham R, Buxbaum S, Link J. Determination of binding constants of diabodies directed against prostate-specific antigen using electrochemiluminescence-based immunoassays [J]. J Mol Recognit, 1996, 9 :5-6; 456-461.
[54] Hudson P, Kortt A A. High avidity scFv mμltimers: diabodies and triabodies[J]. J Immunol Methods, 1999,231: 177-189.
[55] Iliades P, Kortt A A, Hudson P J. Triabodies: single chain Fv fragments without a linker form trivalent trimers. [J]. FEBS Lett, 1997, 409(3): 437- 441.
[56] Atwell J, Brehency K A, Lawrence L J. scFv mμltimers of the anti- neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies [J]. Protein Eng, 1999, 12: 597-604.
[57] Huston J S, Levinson D, Mudgett M. Protein engineering of antibody binding site: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Eschenchia coli[J]. Proc Natl Acad Sci USA, 1988, 85: 5879-5887
[58] Anand N N, Mandal S, Mackenzie C R. Bacterialexpression and secretion of singlechain Fv gene encoding proteins for a salmonella serotye B O-antigen[J]. The Journal of Biological Chemistry, 1991, 266: 21874-21882.
[59] Page M J, Sydenham M A. High lever expression of the humanized monoclonal antibody CAMPATH-1H in Chinese hamster ovary cells[J]. Biotechnology, 1991, 9(l): 64-68.
[60] Duan L, Bagasra O, Laughlin M A, et al. Potent inhibition of human immunodeficiency virus type I replication by an intracellμlar anti-REV single-chain antibody[J]. Proc Natl Acad Sci USA. 1994, 91: 5075.
[61] Arafat WO, Gomez-Navarro J, Buchsbaum DJ, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 2002 Feb; 9(4): 256-62.
[62] Tsumato K, Shinoki K, Kondo H. Highly efficient recover of functional single-chain Fv frament from inclusion bodies overexpressed in Escherichia coli by contrlled introduction of exidizing zeagent-applicaation to a human single-chain Fv fragment[J]. Journal of Immunological Methods, 1998, 219: 119-128.
[63] Vorma R, Bolati E, George A J T. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systerms[J]. J Immunol Methods, 1998, 216: 165-181.
[64] Su Y C, Lim K P, Nathan S. Bacterial expression of the scFv fragment of a recombinant antibody specific for Burkholderia pseudomallei exotoxin[J]. J Biochem Mol Biol. 2003 36 (5): 493-498.
[65] Fischer R, Drossard J, Emans N. Towards molecμlar farming in the future:Pichia pastoris-based production of single-chain antibody fragments[J]. Biotechnol Appl Biochem, 1999, 30: 117-120.
[66] Wood C R, Boss M A, Kenten J H. The synthesis and in vivo assembly of functional antibodies in yeast[J]. Nature, 1985, 314: 446-449.
[67] Shi X, Karkut T, Chamankhah M. Optimal conditions for the expression of a single-chain antibody (scFv) gene in Pichia pastoris[J]. Protein Expr Purif, 2003 Apr; 28(2): 321-330.
[68] Powers D B, Amersdorfer P, Poμl M. Expression of single-chain Fv-Fc fusions in Pichia pastoris[J]. J Immunol Methods, 2001, 251: 123-135.
[69] Eldin P, Pauza M E, Heida Y High level secretion of two antibody single chain Fv fragments by Pichia pastoris[J]. J Immunol Methods, 1997, 201: 67-75.
[70] Freyre F M, Vazquez J E, Ayala M. Very high expression of an anti- carcinoembryonic antigen single chain Fv antibody fragment in the yeast Pchia pastoris[J]. Journol of Biotechnology, 2000, 76: 157-163.
[71] Brocks B, Rode H J, Klein M. A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells[J]. Immunotechnology, 1997, 3(3): 173-184.
[72] Lemeμlle C, Chardes T, Montavon C. Anti-digoxin scFv fragments expressed in bacteria and in insect cells have different. antigen binding properties[J]. FEBS Lett. 1998, 423 (2): 159-166.
[73] [81] Kretzschmar T, Aoustin L, Zingel O. High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies[J]. J Immunol Methods. 1996, 195 (1-2): 93-101.
[74] Dutbecco R: US Patent No.4953002, 1986.
[75] Smith G P Filanentous fusion phage: novel expression vector that display cloned antigenes on the viron surface[J].Science, 1985, 228: 1315-1317.
[76] McCafferty J, Griffiths A D, Winter G. Phage antibodies: filamentous displaying antibody varialole domains[J]. Nature, 1990, 348: 552-554.
[77] Webste R E. Biology of the filamentous phage [M]. A Labouratory Manunl. Academic Press, New York, 1996, 1-20.
[78] Model P, Russel M. Filamentous bacterial phage [J]. The Bacteriophage, 1998, 2: 375-456.
[79] Clackson T, Well JA. In vitro selection from protein and peptide libraries [J]. Trends Biotechnol, 1994, (12): 173-184.
[80] Fuh G, Sidhu SS. Efficient phage display of polypeptides fused to the carboxy-terminus of the M13 gene-3 minor coat protein [J]. FEBS Lett, 2000, 480(1-2): 231-234.
[81] Jespers L S, Messens J H, De Keyser A. Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI [J]. Bio Technology. 1995, 13:378-382.
[82] Brinkmann U, Chowdhury D, Roscoe D M. Phage display of disμlfide- stabilized Fv fragments [J]. J Immunol Methods, 1995, 182: 4150-4162.
[83] McGuinness B T, Walter Q FitzGerald K. Phage diabody repertoires for selection of larger numbers of bispecific antibody fragments [J]. Nat Biotechnol, 1996, 14: 1149-1154.
[84] Barbas C F, Lerner·R A. Combinatorial immunoglobμlin libraries on the surface·of phage (phabs): rapid selection of antigen-specific Fabs [J]. Methods: A Companion to Methods in Enzymology, 1991, 2: 119-124.
[85] Hoogenboom H R, Griffiths A D, Johnson K S. Mμlti-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody(Fab) heavyand light chains [J]. Nucl Acids Res, 1991, 19: 4133-4137.
[86] Barbas C F, Bain J D, Hoekstra D M. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem [J]. Proc Natl Acad Sci USA, 1992, (59): 4457-4461。
[87] Hoogenboom H R, Winter G By-passing immunization. Human antibodies from synthetic repertoires of gremlin VH gene segments rearranged in vitro [J]. J Mol Biol, 1992, 227 (2): 381-388.
[88] Perter P, Liming G. Benhard V HUCAL: the fμlly synthetic human combinatorial antibody library [M]. In Wendy H ed. Antibody Engineering II: new technology, application & commercialization. C A, USA: IBC Press. 1997, 273-301.
[89] Marks J D, Hoogenboom H R, Bonnert T P. By-passing immunization. Human antibodies from V-gene libraries displayed on phage [J]. J Mol Bia1, 1991, (222): 581-597.
[90] Griffiths A D, Williams S C, Hartley O. Isolation of high affinity human antibodies directly from large synthetic repertoires [J]. EMBO J, 1994, (13): 3245-3260.
[91] Zdanov A, Li Y, Bundle D R1. Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigene at 1.7-Aresolution [J]. PNAS, 1994, 91(14): 6423-6427.
[92] Burton D R. Monoclonal antibody from combinatorial libraries [J]. Acc Chem Res, 1993, 26:405.
[93] Greenman J, Jones E, Wright M D. The use of intracellμlar single chain antibody fragments to inhibit specifically the expression of cell surface molecμles [J]. J Immunol Meth, 1996, 194 (2): 169-180.
[94] Persic L, Righi M, Roberts A. Targeting vectors for intra cellμlarimmunization [J]. Gene, 1997, 87 (l): 1-8.
[95] George A J, Jamar F, Tai M S. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide [J]. Proc Natl Acad Sci USA, 1995, 92: 8358-8362.
[96] Reiter Y, Wright A F, Tonge D W. Recombinant single-chain and disμlfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice [J]. Int J Cancer, 1996, 67(1): 113-123.
[97] Wels W, Beerli R, Hellmann P EGF receptor and P185erbB-2-specific single chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins [J]. Int J Cancer, 1995, 60: 137-142.
[98] Abler L L, Sheets M D. Expression of scFv antibodies in Xenopus embryos to disrupt protein function: implications for large-scale evaluation of the embryonic proteome. Genesis, 2003, 35 (2): 107-113.
[99] 董志伟, 王琰. 抗体工程[M]. 北京: 北京医科大学出版社, 2002, 222-223.
[100] 朱立平, 陈学清. 免疫学常用实验方法[M]. 北京: 人民军医出版社, 2000, 24-25; 55-56.
[101] J. 萨姆布鲁克, E.F. 弗里奇, T. 曼尼阿蒂斯. 分子克隆实验指南(第二版)[M]. 北京: 科学出版社, 1999, 888-897.
[102] 卢圣栋. 现代分子生物学实验技术. 中国协和医科大学出版社第二版, 2001
[103] 冯小黎. 重组包涵体蛋白质的折叠复性. 生物化学与生物物理进展,2001, 28(4): 482-485.
[104] 章谷生,容秉培.单克隆抗体在医学上的应用[M].上海:科学技术出版社,1987:2812406
[105] 曹军平, 闫桂玲, 刘秀梵等 两种简易高效的单克隆抗体提纯方法[J] 单克隆抗体通讯 1995,11(2):52-54
[106] 雷祚荣. 细菌毒素分子生物学[M]. 北京:中国科学技术出版社, 1993. 132
[107] 万忠海, 王景林, 江禹等 绿脓杆菌外毒素 A 受体结合区蛋白基因重组与鉴定[J] 中国兽医学报, 2002(6):571-573
[108] 万忠海, 何畅, 江禹等 重组绿脓杆菌外毒素 A 受体结合区蛋白动物免疫保护试验[J] 中国兽医学报, 2001(4):359-361
[109] 曹军平,闫桂玲,刘秀樊,等.两种简易高效的单克隆抗体纯化方法.单克隆抗体通讯,1995,11(2):52~54
[110] 谭文庆.单链抗体的研究进展[J].国外医学-放射医学核医学分册,2001,25(2):55-59.
[111] 林学颜,张 玲.现代细胞与分子免疫学[M].北京:科学出版社 1999:49
[112] 谭文庆.单链抗体的研究进展[J].国外医学-放射医学核医学分册,2001,25(2):55-59.
[113] VermaR, BoletiE, GeorgeAJ. Antibody engineering: Compariso of bacterial, yeast, insectand mammalian expression systems [J]. Immunol Methods,1998,216(1-2):165-181.
[114] 黄 , 寿 成 超 . 噬 菌 体 抗 体 库 技 术 的 研 究 进 展 [J]. 细 胞 生 物 学 杂志,2002,24(1):1-4.
[115] Adey NB, Mataragnon AH, Rider JE, etal. Characterization of phage that bind plastic from phage-displayed random peptide li-braries [J]. Gene, 1995, 156(1):27-31.
[116] Mark JD, Hoogenboom HR, Bonnert TP, etal. By-passingim-munization: Human antibodies from V-gene libraries display edon phage [J]. MolBiol, 1991, 222(3): 581-597.
[117] Colcher D, Bird R, Roselli M, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst. 1990;82(14):1191
[118] Fitzgerald K, Holliger P, Winter G, et al. Improved tumor targeting by disμlphide stabilized diabodes expressed in Pichia pastoris. Protein Eng, 1997;10(10):1221
[119] Deshane J, Cabrera G, Grim JE, et al. Targeted eradication of ovarian cancer mediated by intracellμlar expressionof anti-erbB2 single-chain antibody. Gyn Onool, 1995;59(1):8
[120] Wels W, Beerli R, Helimann P, et a1. EGF receptor and p185 erbB2 specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer, 1995;60(1):137
[121] Benhar I, Reiter Y, Pai LH, et al. Administration of disμlfide-stabilized Fv-inurwnotoxins Bl(dsFv)一 PE3S and B3 ( dsFv)一PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int JCancer, 1995;62(3):35L
[122] Zhu Z, Zapata G, Shalaby R, et al. High level secretion of a hununized bispecific diabody from Escherichia coli Nature Biotechnology, 1996;14(2):192
[2] 方之扬。烧伤理论与实践。沈阳:辽宁科学出版社,1989
[3] 黎鳌。烧伤学。上海:上海科学技术出版社,2001:1-3
[4] 郭振荣。危重烧伤的概念。北京:科学出版社,2000:1-2
[5] 孙永华。现代烧伤治疗与手术图谱。北京:人民军医出版社,2004
[6] 葛绳德 . 反之烧伤后感染的指导意见.应用抗菌药物防止外科感染的指导意见(草案).中华外科杂志,2003,41(4):267
[7] 李家泰 . 中国细菌耐药监测研究.中华医学杂志,2001,81(1):8
[8] Curtis P. Artz and John A.. Moncrief, ed. The Treatment Of Burns. Philadelphia, W.B. saunders, 1969:1-19
[9] Yang Chi-chun, ed. Treatment of burns, Berlin, shanghai Scientific and Technical Publishers Springer-Verlag, 1982:1-7
[10] Fang Zhi-yang, Sheng Zhi-yong, Li Ngao, Ge Sheng-de, ed. Modern treatment of severe burns. Berlin, Springer-Verlag, 1992:1-6
[11] 刘义宁 . 应重视实践与浓度依赖性抗生素的合理应用.中华医学杂志,2001,81(1):5
[12] 孙永华 . 烧伤脓毒症与多脏器功能障碍综合征 . 中华烧伤杂志,2001,17(3):189
[13] 肖光夏 . 烧伤院内感染的两个问题.中华烧伤杂志,2004,20(1):4
[14] Lari AR. Nosocomial infection in an Iranian burn care center.Burns,2000,26:737
[15] 徐盈斌 . 1993、1999 年烧伤科细菌学调查及耐药性分析.中华烧伤杂志,2002,18(2):159
[16] 许 伟 石 . 烧 伤 感 染 的 经 验 性 应 用 抗 生 素 问 题 . 中 华 烧 伤 杂志,2000,16(1):72
[17] David N. Herndon ed. Total burn care. London, Saunders, 2002
[18] Dalamaga M. Stenotrophomonas maltophilia:A serious ang rare complication in parients suffering from burns. Burns,2003,29:711
[19] Kooistra-Smid M.. Molecμlar epideniolgy of Staphylococcus aureus colonization in a burn center.Burns,2004,30:27
[20] 许 伟 石 . 烧 伤 感 染 的 经 验 性 应 用 抗 生 素 问 题 , 中 华 烧 伤 杂志,2002,18(1):71
[21] 姚咏明 . 烧伤脓毒症的诊断标准与防治.中华烧伤杂志, 2003,20(1):65
[22] Mason WL.Colonization of burns and the durarion of hospital stay of severely burned patients, J Hospital Infect,1992,22:55
[23] Pandit DV. Laboratory data fron the surveillance Of a burn ward for the detection of hospital infection.Burns, 1993,19:52
[24] Pruitt BA. Burn wound infection: current status.World J Surg,1998,22:135
[25] 张婴元 . 细菌耐药趋势与抗药感染治疗的若干问题.中华医学杂志,2001,81(1):2
[26] 中华人民共和国卫生部,医院感染诊断标准(试行).中华烧伤杂志,2001,81(4):314
[27] 卓 超 . 嗜麦芽窄食单胞菌院内感染的危险因素及耐药分析.中华烧伤杂志,2004,20(1):10
[28] Agnihotri N. Aerobic bacterial isolates from burn wound ingections and their antibiograms-a five year study.Burns,2004,30:241
[29] Tredge EE. Pseudomonas in the thermally injured patient-a review. Burns,2004,30:3
[30] 李景玉. 绿脓杆菌外毒素 A 及其抗毒素,微生物学免疫学进展,1995,23(3):184~186。
[31] 杜世或. 绿脓杆菌外毒素 A 的结构,功能及其重组毒素,生物化学与生物物理进展,1995,22(2)112~117。
[32] 敬德仲,尤旭. 绿脓杆菌外毒素 A 研究进展,生物技术,1994,4(1):1~4。
[33] Batra JK, Jinno Y, Chraudhrary VK. Antitumor activity in mice of an immunotoxin made withr anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8545-9.
[34] Liu EA, Fuerst TR, Moss B. A soluble recombinant polypeptide comprising thre amino-terminal hralf of thre extracellμlar region of thre CD4 molecμle contains an active binding site for hruman immunodeficiency virus. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2357-61.
[35] Case JP, Lorberboum-Galski HR, Lafyatis R. Chrimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthrritis in rats. Proc Natl Acad Sci U S A. 1989 Jan;86(1):287-91.
[36] Allured VS, Collier RJ, Carroll SF. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1320-4.
[37] Chraudhrary VK, Jinno Y, FitzGerald D. Pseudomonas exotoxin contains a specific sequence at thre carboxyl terminus thrat is required for cytotoxicity. Proc Natl Acad Sci U S A. 1990 Jan;87(1):308-12.
[38] Chraudhrary VK, FitzGerald DJ, Adhrya S. Activity of a recombinant fusion protein between transforming growthr factor type alphra andPseudomonas toxin. Proc Natl Acad Sci U S A. 1987 Jμl;84(13):4538-42.
[39] 高基民. 绿脓杆菌外毒素 A 研究进展,国外医学微生物学分册,1993,16(2):72~75。
[40] Chrristophrer C.R. Grant and Michrael L.Vasil Analysis of transcription of exotoxin a gene of pseudomonas aeruginosa Journal of Bacteriology ,1986 , 168 :1112
[41] 胡福泉. 绿脓杆菌外毒素 A 的结构与功能,国外医学微生物学分册,1990,(4):175~177。
[42] Epstein SE, Siegall CB, Biro S. Cytotoxic effects of a recombinant chrimeric toxin on rapidly proliferating vascμlar smoothr muscle cells. Circμlation. 1991 Aug;84(2):778-87.
[43] 罗海波主编. 细菌毒素研究进展. 北京:人民卫生出版社. 1983. 182
[44] HRall WA, Merrill MJ, Walbridge S. Epidermal growthr factor receptors on ependymomas and othrer brain tumors.J Neurosurg. 1990 Apr;72(4):641-6.
[45] 韩文瑜。现代分子细菌学,61~65。
[46] Chraudry GJ, Wilson RB, Draper RK. A dipeptide insertion in domain I of exotoxin A thrat impairs receptor binding. J Biol Chrem. 1989 Sep 5;264(25):15151-6.
[47] HRwang J, Fitzgerald D J, Adhrya et al. Functional domains of Pseudomonas exotoxin identified by dilution analysis of thre gene expressed in E coli. Cell. 1987,48:129～136
[48] Jana HRaase Erichr Lanka A specific protease encoded by thre conjugative DNA transfer systems of IncP and Ti plasmids is essential for pilus sythresis Journal of bacteriology 1997 , 179: 5728
[49] 杨之骏主编. 烧伤治疗. 上海:上海科技出版社,1985.87～97
[50] Reiter Y, Brinkmann U, Lee B. Engineering antibodyi Fv fragments for cancer detection and therapy: disμlfide stabilized Fv fragment[J]. Nature Biotechnol, 1996, 14: 1239-1245.
[51] Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments[J ] . Proe Natl Acad Sci, 1993, 90: 6444-6448.
[52] Abraham R, Buxbaum S, Link J. Screening and kinetic analysis of recombinant anti-CEA antibody fragments[J]. Immunol Methods, 1995, 183: 119-125.
[53] Abraham R, Buxbaum S, Link J. Determination of binding constants of diabodies directed against prostate-specific antigen using electrochemiluminescence-based immunoassays [J]. J Mol Recognit, 1996, 9 :5-6; 456-461.
[54] Hudson P, Kortt A A. High avidity scFv mμltimers: diabodies and triabodies[J]. J Immunol Methods, 1999,231: 177-189.
[55] Iliades P, Kortt A A, Hudson P J. Triabodies: single chain Fv fragments without a linker form trivalent trimers. [J]. FEBS Lett, 1997, 409(3): 437- 441.
[56] Atwell J, Brehency K A, Lawrence L J. scFv mμltimers of the anti- neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies [J]. Protein Eng, 1999, 12: 597-604.
[57] Huston J S, Levinson D, Mudgett M. Protein engineering of antibody binding site: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Eschenchia coli[J]. Proc Natl Acad Sci USA, 1988, 85: 5879-5887
[58] Anand N N, Mandal S, Mackenzie C R. Bacterialexpression and secretion of singlechain Fv gene encoding proteins for a salmonella serotye B O-antigen[J]. The Journal of Biological Chemistry, 1991, 266: 21874-21882.
[59] Page M J, Sydenham M A. High lever expression of the humanized monoclonal antibody CAMPATH-1H in Chinese hamster ovary cells[J]. Biotechnology, 1991, 9(l): 64-68.
[60] Duan L, Bagasra O, Laughlin M A, et al. Potent inhibition of human immunodeficiency virus type I replication by an intracellμlar anti-REV single-chain antibody[J]. Proc Natl Acad Sci USA. 1994, 91: 5075.
[61] Arafat WO, Gomez-Navarro J, Buchsbaum DJ, et al. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther. 2002 Feb; 9(4): 256-62.
[62] Tsumato K, Shinoki K, Kondo H. Highly efficient recover of functional single-chain Fv frament from inclusion bodies overexpressed in Escherichia coli by contrlled introduction of exidizing zeagent-applicaation to a human single-chain Fv fragment[J]. Journal of Immunological Methods, 1998, 219: 119-128.
[63] Vorma R, Bolati E, George A J T. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systerms[J]. J Immunol Methods, 1998, 216: 165-181.
[64] Su Y C, Lim K P, Nathan S. Bacterial expression of the scFv fragment of a recombinant antibody specific for Burkholderia pseudomallei exotoxin[J]. J Biochem Mol Biol. 2003 36 (5): 493-498.
[65] Fischer R, Drossard J, Emans N. Towards molecμlar farming in the future:Pichia pastoris-based production of single-chain antibody fragments[J]. Biotechnol Appl Biochem, 1999, 30: 117-120.
[66] Wood C R, Boss M A, Kenten J H. The synthesis and in vivo assembly of functional antibodies in yeast[J]. Nature, 1985, 314: 446-449.
[67] Shi X, Karkut T, Chamankhah M. Optimal conditions for the expression of a single-chain antibody (scFv) gene in Pichia pastoris[J]. Protein Expr Purif, 2003 Apr; 28(2): 321-330.
[68] Powers D B, Amersdorfer P, Poμl M. Expression of single-chain Fv-Fc fusions in Pichia pastoris[J]. J Immunol Methods, 2001, 251: 123-135.
[69] Eldin P, Pauza M E, Heida Y High level secretion of two antibody single chain Fv fragments by Pichia pastoris[J]. J Immunol Methods, 1997, 201: 67-75.
[70] Freyre F M, Vazquez J E, Ayala M. Very high expression of an anti- carcinoembryonic antigen single chain Fv antibody fragment in the yeast Pchia pastoris[J]. Journol of Biotechnology, 2000, 76: 157-163.
[71] Brocks B, Rode H J, Klein M. A TNF receptor antagonistic scFv, which is not secreted in mammalian cells, is expressed as a soluble mono- and bivalent scFv derivative in insect cells[J]. Immunotechnology, 1997, 3(3): 173-184.
[72] Lemeμlle C, Chardes T, Montavon C. Anti-digoxin scFv fragments expressed in bacteria and in insect cells have different. antigen binding properties[J]. FEBS Lett. 1998, 423 (2): 159-166.
[73] [81] Kretzschmar T, Aoustin L, Zingel O. High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies[J]. J Immunol Methods. 1996, 195 (1-2): 93-101.
[74] Dutbecco R: US Patent No.4953002, 1986.
[75] Smith G P Filanentous fusion phage: novel expression vector that display cloned antigenes on the viron surface[J].Science, 1985, 228: 1315-1317.
[76] McCafferty J, Griffiths A D, Winter G. Phage antibodies: filamentous displaying antibody varialole domains[J]. Nature, 1990, 348: 552-554.
[77] Webste R E. Biology of the filamentous phage [M]. A Labouratory Manunl. Academic Press, New York, 1996, 1-20.
[78] Model P, Russel M. Filamentous bacterial phage [J]. The Bacteriophage, 1998, 2: 375-456.
[79] Clackson T, Well JA. In vitro selection from protein and peptide libraries [J]. Trends Biotechnol, 1994, (12): 173-184.
[80] Fuh G, Sidhu SS. Efficient phage display of polypeptides fused to the carboxy-terminus of the M13 gene-3 minor coat protein [J]. FEBS Lett, 2000, 480(1-2): 231-234.
[81] Jespers L S, Messens J H, De Keyser A. Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI [J]. Bio Technology. 1995, 13:378-382.
[82] Brinkmann U, Chowdhury D, Roscoe D M. Phage display of disμlfide- stabilized Fv fragments [J]. J Immunol Methods, 1995, 182: 4150-4162.
[83] McGuinness B T, Walter Q FitzGerald K. Phage diabody repertoires for selection of larger numbers of bispecific antibody fragments [J]. Nat Biotechnol, 1996, 14: 1149-1154.
[84] Barbas C F, Lerner·R A. Combinatorial immunoglobμlin libraries on the surface·of phage (phabs): rapid selection of antigen-specific Fabs [J]. Methods: A Companion to Methods in Enzymology, 1991, 2: 119-124.
[85] Hoogenboom H R, Griffiths A D, Johnson K S. Mμlti-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody(Fab) heavyand light chains [J]. Nucl Acids Res, 1991, 19: 4133-4137.
[86] Barbas C F, Bain J D, Hoekstra D M. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem [J]. Proc Natl Acad Sci USA, 1992, (59): 4457-4461。
[87] Hoogenboom H R, Winter G By-passing immunization. Human antibodies from synthetic repertoires of gremlin VH gene segments rearranged in vitro [J]. J Mol Biol, 1992, 227 (2): 381-388.
[88] Perter P, Liming G. Benhard V HUCAL: the fμlly synthetic human combinatorial antibody library [M]. In Wendy H ed. Antibody Engineering II: new technology, application & commercialization. C A, USA: IBC Press. 1997, 273-301.
[89] Marks J D, Hoogenboom H R, Bonnert T P. By-passing immunization. Human antibodies from V-gene libraries displayed on phage [J]. J Mol Bia1, 1991, (222): 581-597.
[90] Griffiths A D, Williams S C, Hartley O. Isolation of high affinity human antibodies directly from large synthetic repertoires [J]. EMBO J, 1994, (13): 3245-3260.
[91] Zdanov A, Li Y, Bundle D R1. Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigene at 1.7-Aresolution [J]. PNAS, 1994, 91(14): 6423-6427.
[92] Burton D R. Monoclonal antibody from combinatorial libraries [J]. Acc Chem Res, 1993, 26:405.
[93] Greenman J, Jones E, Wright M D. The use of intracellμlar single chain antibody fragments to inhibit specifically the expression of cell surface molecμles [J]. J Immunol Meth, 1996, 194 (2): 169-180.
[94] Persic L, Righi M, Roberts A. Targeting vectors for intra cellμlarimmunization [J]. Gene, 1997, 87 (l): 1-8.
[95] George A J, Jamar F, Tai M S. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide [J]. Proc Natl Acad Sci USA, 1995, 92: 8358-8362.
[96] Reiter Y, Wright A F, Tonge D W. Recombinant single-chain and disμlfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice [J]. Int J Cancer, 1996, 67(1): 113-123.
[97] Wels W, Beerli R, Hellmann P EGF receptor and P185erbB-2-specific single chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins [J]. Int J Cancer, 1995, 60: 137-142.
[98] Abler L L, Sheets M D. Expression of scFv antibodies in Xenopus embryos to disrupt protein function: implications for large-scale evaluation of the embryonic proteome. Genesis, 2003, 35 (2): 107-113.
[99] 董志伟, 王琰. 抗体工程[M]. 北京: 北京医科大学出版社, 2002, 222-223.
[100] 朱立平, 陈学清. 免疫学常用实验方法[M]. 北京: 人民军医出版社, 2000, 24-25; 55-56.
[101] J. 萨姆布鲁克, E.F. 弗里奇, T. 曼尼阿蒂斯. 分子克隆实验指南(第二版)[M]. 北京: 科学出版社, 1999, 888-897.
[102] 卢圣栋. 现代分子生物学实验技术. 中国协和医科大学出版社第二版, 2001
[103] 冯小黎. 重组包涵体蛋白质的折叠复性. 生物化学与生物物理进展,2001, 28(4): 482-485.
[104] 章谷生,容秉培.单克隆抗体在医学上的应用[M].上海:科学技术出版社,1987:2812406
[105] 曹军平, 闫桂玲, 刘秀梵等 两种简易高效的单克隆抗体提纯方法[J] 单克隆抗体通讯 1995,11(2):52-54
[106] 雷祚荣. 细菌毒素分子生物学[M]. 北京:中国科学技术出版社, 1993. 132
[107] 万忠海, 王景林, 江禹等 绿脓杆菌外毒素 A 受体结合区蛋白基因重组与鉴定[J] 中国兽医学报, 2002(6):571-573
[108] 万忠海, 何畅, 江禹等 重组绿脓杆菌外毒素 A 受体结合区蛋白动物免疫保护试验[J] 中国兽医学报, 2001(4):359-361
[109] 曹军平,闫桂玲,刘秀樊,等.两种简易高效的单克隆抗体纯化方法.单克隆抗体通讯,1995,11(2):52~54
[110] 谭文庆.单链抗体的研究进展[J].国外医学-放射医学核医学分册,2001,25(2):55-59.
[111] 林学颜,张 玲.现代细胞与分子免疫学[M].北京:科学出版社 1999:49
[112] 谭文庆.单链抗体的研究进展[J].国外医学-放射医学核医学分册,2001,25(2):55-59.
[113] VermaR, BoletiE, GeorgeAJ. Antibody engineering: Compariso of bacterial, yeast, insectand mammalian expression systems [J]. Immunol Methods,1998,216(1-2):165-181.
[114] 黄 , 寿 成 超 . 噬 菌 体 抗 体 库 技 术 的 研 究 进 展 [J]. 细 胞 生 物 学 杂志,2002,24(1):1-4.
[115] Adey NB, Mataragnon AH, Rider JE, etal. Characterization of phage that bind plastic from phage-displayed random peptide li-braries [J]. Gene, 1995, 156(1):27-31.
[116] Mark JD, Hoogenboom HR, Bonnert TP, etal. By-passingim-munization: Human antibodies from V-gene libraries display edon phage [J]. MolBiol, 1991, 222(3): 581-597.
[117] Colcher D, Bird R, Roselli M, et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst. 1990;82(14):1191
[118] Fitzgerald K, Holliger P, Winter G, et al. Improved tumor targeting by disμlphide stabilized diabodes expressed in Pichia pastoris. Protein Eng, 1997;10(10):1221
[119] Deshane J, Cabrera G, Grim JE, et al. Targeted eradication of ovarian cancer mediated by intracellμlar expressionof anti-erbB2 single-chain antibody. Gyn Onool, 1995;59(1):8
[120] Wels W, Beerli R, Helimann P, et a1. EGF receptor and p185 erbB2 specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer, 1995;60(1):137
[121] Benhar I, Reiter Y, Pai LH, et al. Administration of disμlfide-stabilized Fv-inurwnotoxins Bl(dsFv)一 PE3S and B3 ( dsFv)一PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int JCancer, 1995;62(3):35L
[122] Zhu Z, Zapata G, Shalaby R, et al. High level secretion of a hununized bispecific diabody from Escherichia coli Nature Biotechnology, 1996;14(2):192